Literature DB >> 11577480

Childhood cancer: patterns of protocol participation in a national survey.

S J Shochat1, A M Fremgen, S B Murphy, C Hutchison, S S Donaldson, G M Haase, A J Provisor, R E Clive-Bumpus, D P Winchester.   

Abstract

Cancer is still the chief cause of death by disease in children, ages one to 14. As improved survival rates have been reported for pediatric cancer patients who are treated on controlled clinical trials, it is important to understand the national utilization of such protocols. In 1993, a survey of childhood cancer was conducted by the Commission on Cancer of the American College of Surgeons. Data regarding type of disease, protocol participation, age, sex, race, insurance, and geographical region were voluntarily submitted by more than 200 hospital cancer registries. Included in this study were 2,208 children and adolescents 21 years of age or younger who were diagnosed in 1987, and 2,293 who were diagnosed in 1992. Pediatric centers (i.e., members of the Pediatric Oncology Group or Children's Cancer Group) submitted 55.1% of the cases and other institutions, 44.9%. It was found that more patients treated at pediatric centers were on protocols (53.8%) than were those treated at other institutions (25.1%). In general, the younger the patient (five years of age or younger), the greater the chance of being on protocol (pediatric centers, 63.7%; others, 42.0%), with very poor adolescent protocol participation (pediatric centers, 34.8%; others, 12.1%). Nevertheless, overall protocol participation was still lower than expected, even in children younger than five years of age, and adolescent participation in controlled clinical trials was low and similar to adult figures. The percentage of childhood cancer cases seen at pediatric centers was smaller than in other series. It was concluded that pediatric cancer centers need to continue to encourage patient participation in controlled clinical trials, with special emphasis on adolescents.

Entities:  

Mesh:

Year:  2001        PMID: 11577480     DOI: 10.3322/canjclin.51.2.119

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  11 in total

1.  Barriers and facilitators of clinical trial enrollment in a network of community-based pediatric oncology clinics.

Authors:  Carolyn Russo; Linda Stout; Toni House; Victor M Santana
Journal:  Pediatr Blood Cancer       Date:  2019-09-25       Impact factor: 3.167

2.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Authors:  Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2019-02-07

3.  Participation in pediatric oncology research protocols: Racial/ethnic, language and age-based disparities.

Authors:  Paula Aristizabal; Jenelle Singer; Renee Cooper; Kristen J Wells; Jesse Nodora; Mehrzad Milburn; Sheila Gahagan; Deborah E Schiff; Maria E Martinez
Journal:  Pediatr Blood Cancer       Date:  2015-03-08       Impact factor: 3.167

Review 4.  Nurse-Led Programs to Facilitate Enrollment to Children's Oncology Group Cancer Control Trials.

Authors:  Maureen Haugen; Katherine Patterson Kelly; Marcia Leonard; Denise Mills; Lillian Sung; Catriona Mowbray; Wendy Landier
Journal:  J Pediatr Oncol Nurs       Date:  2015-11-26       Impact factor: 1.636

5.  Patient/Family Education for Newly Diagnosed Pediatric Oncology Patients.

Authors:  Wendy Landier; JoAnn Ahern; Lamia P Barakat; Smita Bhatia; Kristin M Bingen; Patricia G Bondurant; Susan L Cohn; Sarah K Dobrozsi; Maureen Haugen; Ruth Anne Herring; Mary C Hooke; Melissa Martin; Kathryn Murphy; Amy R Newman; Cheryl C Rodgers; Kathleen S Ruccione; Jeneane Sullivan; Marianne Weiss; Janice Withycombe; Lise Yasui; Marilyn Hockenberry
Journal:  J Pediatr Oncol Nurs       Date:  2016-07-09       Impact factor: 1.636

6.  Canadian Study of Determinants of Endometabolic Health in ChIlDrEn (CanDECIDE study): a cohort study protocol examining the mechanisms of obesity in survivors of childhood brain tumours.

Authors:  M Constantine Samaan; Lehana Thabane; Sarah Burrow; Rejane F Dillenburg; Katrin Scheinemann
Journal:  BMJ Open       Date:  2013-06-20       Impact factor: 2.692

7.  Assessment of enrollment characteristics for Children's Oncology Group (COG) upfront therapeutic clinical trials 2004-2015.

Authors:  Kelly E Faulk; Amy Anderson-Mellies; Myles Cockburn; Adam L Green
Journal:  PLoS One       Date:  2020-04-23       Impact factor: 3.240

8.  Assessment of Factors Associated With Parental Perceptions of Voluntary Decisions About Child Participation in Leukemia Clinical Trials.

Authors:  Paula Aristizabal; Arissa K Ma; Nikhil V Kumar; Bianca P Perdomo; Courtney D Thornburg; Maria Elena Martinez; Jesse Nodora
Journal:  JAMA Netw Open       Date:  2021-05-03

9.  Parent perspectives on information about late effects of childhood cancer treatment and their role in initial treatment decision making.

Authors:  Katie A Greenzang; Angela Dauti; Jennifer W Mack
Journal:  Pediatr Blood Cancer       Date:  2018-01-30       Impact factor: 3.838

10.  Prevalence of Oral Complications occurring in a Population of Pediatric Cancer Patients receiving Chemotherapy.

Authors:  Kapil Gandhi; Geetika Datta; Shilpa Ahuja; Tanvi Saxena; Ankush G Datta
Journal:  Int J Clin Pediatr Dent       Date:  2017-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.